Clinical trials: Hematological Malignancies
Hematologic Cancer
Virtual Reality Intervention to Improve Comfort in Hospitalized Hematology Patients
The objective of this clinical trial is to determine whether virtual reality (VR) devices can improve comfort and quality of life in hospitalized adult patients with hematological malignancies who require at least 15 consecutive…
- Trial name
- NCT07894601
- Testing
- Immersive virtual reality experience
- Where
- 2 sites in Spain
- Volunteers
- 145 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Myeloproliferative Disorders, Leukemia
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00827099
- Testing
- anti-thymocyte globulin, fludarabine phosphate, Melphalan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Northside Hospital, Inc.
Thrombocytopenia, Hematologic Malignancy
Thrombosomes® in Bleeding Thrombocytopenic Patients Study
This prospective, multicenter, randomized, open-label, Phase 2, parallel, dose ranging, multidose trial will enroll patients into 3 Thrombosomes dose groups and 1 control liquid stored platelets (LSP) group in order to evaluate…
- Conditions
- Thrombocytopenia, Hematologic Malignancy, Bone Marrow Aplasia, Myeloproliferative Disorders
- Trial name
- NCT04631211
- Testing
- Thrombosomes, Liquid Stored Platelets (LSP)
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 21 people
- Sponsor
- Cellphire Therapeutics, Inc.
Septic Shock, Anemia
TRANSfusion in Patients With Onco-hematological Malignancies ResusciTated From Septic Shock
Septic shock is a frequent complication associated with high mortality in patients with malignancies. The best transfusion strategy (restrictive or liberal) for the resuscitation of septic shock remains a controversial issue, in…
- Conditions
- Septic Shock, Anemia, Cancer
- Trial name
- TRANSPORT (NCT03837171)
- Testing
- Liberal Red blood cell transfusion, Restrictive Red blood cell transfusion
- Where
- 20 sites in France
- Volunteers
- 192 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit
This study examines the difference between the quality of care patients receive with palliative care consult services and the palliative care unit.
- Trial name
- NCT02686411
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
This phase I trial tests safety, side effects and best dose of B-cell activating factor receptor (BAFFR)-based chimeric antigen receptor T-cells, with fludarabine and cyclophosphamide lymphodepletion, for the treatment of…
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT06191887
- Testing
- Autologous BAFFR-targeting CAR T Cells, Bendamustine, Biopsy
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Mayo Clinic
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
This phase II MATCH treatment trial identifies the effects of GDC-0032 (taselisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439175
- Testing
- Taselisib
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed Hematologic Malignancy
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant
The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the…
- Trial name
- Haplo-CIK (NCT03821519)
- Testing
- donor-derived CIK cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- A.O. Ospedale Papa Giovanni XXIII
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
This phase I/Ib trial studies the side effects and best dose of ipilimumab or nivolumab in treating patients with cancers of the blood and blood-forming tissues (hematologic cancers) that have returned after a period of…
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Myeloproliferative Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT01822509
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- 13 sites in United States
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098436
- Testing
- laromustine, temozolomide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- Vion Pharmaceuticals
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Identification of Occupational Exposures in Acute Hematologic Malignancy
Lymphoid hemopathies are a group of malignant haematological disorders characterized by clonal proliferation of cells of the lymphoid line.
- Conditions
- Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- RHELYPRO (NCT03316209)
- Where
- 7 sites in France
- Volunteers
- 205 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Blood Cancer
Predictive Markers of Response and Toxicity in Patients With a Haematological Malignancy Treated With Immunotherapy.
Immunotherapies have substantially improved the prognosis of patients with haematological malignancies. While clinical trial data suggest durable complete response rates, markers associated with non-response to treatment are…
- Trial name
- PRONOSTIM (NCT05450367)
- Testing
- Data collection
- Where
- France
- Volunteers
- 249 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematological Malignancies, Leukemia
A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies
This research study uses a drug called cyclophosphamide to decrease the incidence of GVHD in matched sibling hematopoietic stem cell transplant. In doing so, the goal of the study is to increase overall survival.
- Conditions
- Hematological Malignancies, Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT01315132
- Testing
- Matched Sibling Allogeneic Transplantation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Acute Leukemia, Chronic Leukemia
Trial of AVN-944 in Patients With Advanced Hematologic Malignancies
The purpose of this study is to determine the safety and maximum tolerated dose, pharmacokinetics, and anti-neoplastic response of AVN-944 in patients with advanced hematologic malignancies.
- Conditions
- Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma
- Trial name
- NCT00273936
- Testing
- AVN-944 capsules for oral administration
- Where
- 5 sites in United States
- Volunteers
- 72 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
This phase II trial is studying how well umbilical cord blood transplant from a donor works in treating patients with hematological cancer.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia
- Trial name
- NCT00723099
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Hematologic Malignancies
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
The purpose of this study is to determine if the incidence of Graft vs. Host Disease (GVHD) after non-myeloablative transplantation can be reduced by using a combination of three immune suppressive medication; sirolimus…
- Trial name
- NCT00146614
- Testing
- Sirolimus, Tacrolimus, Methotrexate
- Where
- 3 sites in United States
- Volunteers
- 105 people
- Sponsor
- Dana-Farber Cancer Institute
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Hematologic Malignancy, ALL, Childhood
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-ALL, T-ALL) or Lymphoma.
- Conditions
- Hematologic Malignancy, ALL, Childhood, AML, Childhood, Lymphoma
- Trial name
- NCT06326463
- Testing
- Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- St. Jude Children's Research Hospital
Hematologic Neoplasms, Prostatic Neoplasms
Safety Study of APR-246 in Patients With Refractory Hematologic Cancer or Prostate Cancer
The purpose of this study is to determine the highest feasible dose (HFD) of intravenous (IV) APR-246 when given to patients with refractory hematologic malignancies or prostate carcinoma.
- Trial name
- NCT00900614
- Testing
- APR-246
- Where
- 6 sites in Sweden
- Volunteers
- 36 people
- Sponsor
- Aprea Therapeutics
Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia
A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy
This study is a single-center, open-label clinical trial of single-dose of CAR T-cells in subjects with relapsed/refractory hematologic malignancy.
- Trial name
- NCT06756321
- Testing
- anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Affiliated Hospital of Nantong University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.